10.1M XNYS Volume
XNYS 19 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Michael Marinaro | EVP & President, Surgical OU | Payment of exercise price or tax liability using portion of securities received from the company at price $ 94.30 per share. | 03 Mar 2025 | 575 | 40,675 (0%) | 0% | 94.3 | 54,223 | Ordinary Shares |
| Thierry Pieton | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 29,574 | 29,574 | - | - | Stock Option (Right to Buy) | |
| Thierry Pieton | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 10,605 | 10,605 | - | - | Performance Share Unit | |
| Thierry Pieton | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 94.30 per share. | 03 Mar 2025 | 26,512 | 30,754 (0%) | 0% | 94.3 | 2,500,082 | Ordinary Shares |
| Thierry Pieton | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 94.30 per share. | 03 Mar 2025 | 4,242 | 4,242 (0%) | 0% | 94.3 | 400,021 | Ordinary Shares |
| Thierry Pieton | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 29,574 | 29,574 | - | - | Stock Option (Right to Buy) | |
| Thierry Pieton | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 26,512 | 30,754 (0%) | 0% | 0 | Ordinary Shares | |
| Thierry Pieton | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 4,242 | 4,242 (0%) | 0% | 0 | Ordinary Shares | |
| Geoffrey S. Martha | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2025 | 34,741 | 0 | - | - | Stock Option (Right to Buy) | |
| Geoffrey S. Martha | Director, Chairman and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 92.46 per share. | 27 Jan 2025 | 30,184 | 186,770 (0%) | 0% | 92.5 | 2,790,813 | Ordinary Shares |
| Geoffrey S. Martha | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 74.84 per share. | 27 Jan 2025 | 34,741 | 216,954 (0%) | 0% | 74.8 | 2,600,016 | Ordinary Shares |
| Michael Marinaro | EVP & President, Surgical OU | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2025 | 2,345 | 0 | - | - | Stock Option (Right to Buy) | |
| Michael Marinaro | EVP & President, Surgical OU | Exercise or conversion of derivative security received from the company (such as an option) at price $ 74.84 per share. | 27 Jan 2025 | 2,345 | 43,323 (0%) | 0% | 74.8 | 175,500 | Ordinary Shares |
| Michael Marinaro | EVP & President, Surgical OU | Payment of exercise price or tax liability using portion of securities received from the company at price $ 92.46 per share. | 27 Jan 2025 | 2,073 | 41,250 (0%) | 0% | 92.5 | 191,670 | Ordinary Shares |
| Matthew R. Walter | SVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2025 | 1,337 | 0 | - | - | Stock Option (Right to Buy) | |
| Matthew R. Walter | SVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 74.84 per share. | 27 Jan 2025 | 1,337 | 26,997 (0%) | 0% | 74.8 | 100,061 | Ordinary Shares |
| Matthew R. Walter | SVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 92.46 per share. | 27 Jan 2025 | 1,174 | 25,823 (0%) | 0% | 92.5 | 108,548 | Ordinary Shares |
| Brett A. Wall | EVP & Pres Neuroscience | Exercise or conversion of derivative security received from the company (such as an option) at price $ 78.00 per share. | 24 Jan 2025 | 12,437 | 53,416 (0%) | 0% | 78 | 970,086 | Ordinary Shares |
| Brett A. Wall | EVP & Pres Neuroscience | Sale of securities on an exchange or to another person at price $ 90.00 per share. | 24 Jan 2025 | 12,437 | 40,979 (0%) | 0% | 90 | 1,119,330 | Ordinary Shares |
| Brett A. Wall | EVP & Pres Neuroscience | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2025 | 12,437 | 0 | - | - | Stock Option (Right to Buy) | |
| Gary Corona | Interim CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2025 | 11,315 | 44,255 (0%) | 0% | 0 | Ordinary Shares | |
| Ivan K. Fong | EVP GENERAL COUNSEL & SECR | Payment of exercise price or tax liability using portion of securities received from the company at price $ 82.48 per share. | 16 Dec 2024 | 532 | 54,692 (0%) | 0% | 82.5 | 43,879 | Ordinary Shares |
| Brett A. Wall | EVP & Pres Neuroscience | Payment of exercise price or tax liability using portion of securities received from the company at price $ 82.48 per share. | 16 Dec 2024 | 645 | 43,708 (0%) | 0% | 82.5 | 53,200 | Ordinary Shares |
| Geoffrey S. Martha | Director, Chairman and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 82.48 per share. | 16 Dec 2024 | 4,417 | 181,326 (0%) | 0% | 82.5 | 364,314 | Ordinary Shares |
| Sean M. Salmon | EVP & President Cardiovascular | Payment of exercise price or tax liability using portion of securities received from the company at price $ 82.48 per share. | 16 Dec 2024 | 645 | 64,722 (0%) | 0% | 82.5 | 53,200 | Ordinary Shares |
| Ivan K. Fong | EVP GENERAL COUNSEL & SECR | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.58 per share. | 10 Dec 2024 | 3,009 | 55,224 (0%) | 0% | 83.6 | 251,492 | Ordinary Shares |
| Gary Corona | Interim CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 84.01 per share. | 06 Dec 2024 | 662 | 32,721 (0%) | 0% | 84.0 | 55,615 | Ordinary Shares |
| Jennifer M. Kirk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 84.01 per share. | 06 Dec 2024 | 646 | 28,011 (0%) | 0% | 84.0 | 54,270 | Ordinary Shares |
| Michael Marinaro | EVP & President, Surgical OU | Payment of exercise price or tax liability using portion of securities received from the company at price $ 85.38 per share. | 20 Aug 2024 | 2,045 | 40,346 (0%) | 0% | 85.4 | 174,602 | Ordinary Shares |
| Gary Corona | Interim CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 8,966 | 33,035 (0%) | 0% | 0 | Ordinary Shares | |
| Ivan K. Fong | EVP GENERAL COUNSEL & SECR | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.51 per share. | 02 Aug 2024 | 2,985 | 57,963 (0%) | 0% | 81.5 | 243,307 | Ordinary Shares |
| Ivan K. Fong | EVP GENERAL COUNSEL & SECR | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.51 per share. | 02 Aug 2024 | 2,802 | 60,948 (0%) | 0% | 81.5 | 228,391 | Ordinary Shares |
| Ivan K. Fong | EVP GENERAL COUNSEL & SECR | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2024 | 6,144 | 63,750 (0%) | 0% | 0 | Ordinary Shares | |
| Ivan K. Fong | EVP GENERAL COUNSEL & SECR | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.51 per share. | 02 Aug 2024 | 3,423 | 57,606 (0%) | 0% | 81.5 | 279,009 | Ordinary Shares |
| Ivan K. Fong | EVP GENERAL COUNSEL & SECR | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2024 | 8,370 | 61,029 (0%) | 0% | 0 | Ordinary Shares | |
| Ivan K. Fong | EVP GENERAL COUNSEL & SECR | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2024 | 6,144 | 0 | - | - | Performance Share Units | |
| Ivan K. Fong | EVP GENERAL COUNSEL & SECR | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2024 | 8,370 | 0 | - | - | Performance Share Units | |
| Gregory L. Smith | EVP Global Ops & Supply Chain | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2024 | 3,490 | 64,757 (0%) | 0% | 0 | Ordinary Shares | |
| Gregory L. Smith | EVP Global Ops & Supply Chain | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.51 per share. | 02 Aug 2024 | 1,374 | 63,383 (0%) | 0% | 81.5 | 111,995 | Ordinary Shares |
| Gregory L. Smith | EVP Global Ops & Supply Chain | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.51 per share. | 02 Aug 2024 | 1,513 | 61,870 (0%) | 0% | 81.5 | 123,325 | Ordinary Shares |
| Gregory L. Smith | EVP Global Ops & Supply Chain | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2024 | 3,490 | 0 | - | - | Performance Share Units | |
| Brett A. Wall | EVP & Pres Neuroscience | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.51 per share. | 02 Aug 2024 | 2,362 | 46,807 (0%) | 0% | 81.5 | 192,527 | Ordinary Shares |
| Brett A. Wall | EVP & Pres Neuroscience | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2024 | 5,311 | 49,169 (0%) | 0% | 0 | Ordinary Shares | |
| Brett A. Wall | EVP & Pres Neuroscience | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2024 | 5,311 | 0 | - | - | Performance Share Units | |
| Brett A. Wall | EVP & Pres Neuroscience | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.51 per share. | 02 Aug 2024 | 2,701 | 44,106 (0%) | 0% | 81.5 | 220,159 | Ordinary Shares |
| Karen L. Parkhill | EVP & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2024 | 7,132 | 0 | - | - | Performance Share Units | |
| Karen L. Parkhill | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.51 per share. | 02 Aug 2024 | 3,581 | 46,730 (0%) | 0% | 81.5 | 291,887 | Ordinary Shares |
| Karen L. Parkhill | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.51 per share. | 02 Aug 2024 | 3,148 | 50,311 (0%) | 0% | 81.5 | 256,593 | Ordinary Shares |
| Karen L. Parkhill | EVP & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2024 | 7,132 | 53,459 (0%) | 0% | 0 | Ordinary Shares | |
| Geoffrey S. Martha | Director, Chairman and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.51 per share. | 02 Aug 2024 | 8,649 | 194,437 (0%) | 0% | 81.5 | 704,980 | Ordinary Shares |
| Geoffrey S. Martha | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2024 | 18,966 | 203,086 (0%) | 0% | 0 | Ordinary Shares | |
| Geoffrey S. Martha | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2024 | 18,966 | 0 | - | - | Performance Share Units | |
| Geoffrey S. Martha | Director, Chairman and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.51 per share. | 02 Aug 2024 | 9,523 | 184,914 (0%) | 0% | 81.5 | 776,220 | Ordinary Shares |
| Jennifer M. Kirk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.51 per share. | 02 Aug 2024 | 384 | 28,504 (0%) | 0% | 81.5 | 31,300 | Ordinary Shares |
| Jennifer M. Kirk | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2024 | 1,138 | 0 | - | - | Performance Share Units | |
| Jennifer M. Kirk | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2024 | 1,138 | 28,980 (0%) | 0% | 0 | Ordinary Shares | |
| Jennifer M. Kirk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.51 per share. | 02 Aug 2024 | 92 | 28,888 (0%) | 0% | 81.5 | 7,499 | Ordinary Shares |
| Sean Salmon | EVP & President Cardiovascular | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.51 per share. | 02 Aug 2024 | 657 | 67,889 (0%) | 0% | 81.5 | 53,552 | Ordinary Shares |
| Sean Salmon | EVP & President Cardiovascular | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2024 | 5,462 | 68,546 (0%) | 0% | 0 | Ordinary Shares | |
| Sean Salmon | EVP & President Cardiovascular | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2024 | 5,462 | 0 | - | - | Performance Share Units | |
| Sean Salmon | EVP & President Cardiovascular | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.51 per share. | 02 Aug 2024 | 2,779 | 65,110 (0%) | 0% | 81.5 | 226,516 | Ordinary Shares |
| Michael Marinaro | EVP & President, Surgical OU | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2024 | 1,670 | 0 | - | - | Performance Share Unit | |
| Michael Marinaro | EVP & President, Surgical OU | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.51 per share. | 02 Aug 2024 | 847 | 42,391 (0%) | 0% | 81.5 | 69,039 | Ordinary Shares |
| Michael Marinaro | EVP & President, Surgical OU | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.51 per share. | 02 Aug 2024 | 563 | 43,238 (0%) | 0% | 81.5 | 45,890 | Ordinary Shares |
| Michael Marinaro | EVP & President, Surgical OU | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2024 | 1,670 | 43,801 (0%) | 0% | 0 | Ordinary Shares | |
| Matthew R. Walter | SVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.51 per share. | 02 Aug 2024 | 210 | 25,679 (0%) | 0% | 81.5 | 17,117 | Ordinary Shares |
| Matthew R. Walter | SVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2024 | 684 | 0 | - | - | Performance Share Unit | |
| Matthew R. Walter | SVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.51 per share. | 02 Aug 2024 | 231 | 25,448 (0%) | 0% | 81.5 | 18,829 | Ordinary Shares |
| Matthew R. Walter | SVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2024 | 684 | 25,889 (0%) | 0% | 0 | Ordinary Shares | |
| Gregory L. Smith | EVP Global Ops & Supply Chain | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.32 per share. | 31 Jul 2024 | 1,406 | 61,267 (0%) | 0% | 80.3 | 112,930 | Ordinary Shares |
| Ivan K. Fong | EVP GENERAL COUNSEL & SECR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 12,750 | 52,659 (0%) | 0% | 0 | Ordinary Shares | |
| Ivan K. Fong | EVP GENERAL COUNSEL & SECR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 94,248 | 92,248 | - | - | Stock Option (Right to Buy) | |
| Ivan K. Fong | EVP GENERAL COUNSEL & SECR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 31,875 | 31,875 | - | - | Performance Share Unit | |
| Gregory L. Smith | EVP Global Ops & Supply Chain | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 106,260 | 106,260 | - | - | Stock Option (Right to Buy) | |
| Gregory L. Smith | EVP Global Ops & Supply Chain | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 14,375 | 62,673 (0%) | 0% | 0 | Ordinary Shares | |
| Gregory L. Smith | EVP Global Ops & Supply Chain | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 35,938 | 35,938 | - | - | Performance Share Unit | |
| Brett A. Wall | EVP & Pres Neuroscience | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 106,260 | 106,260 | - | - | Stock Option (Right to Buy) | |
| Brett A. Wall | EVP & Pres Neuroscience | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 35,938 | 35,938 | - | - | Performance Share Unit | |
| Brett A. Wall | EVP & Pres Neuroscience | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 14,375 | 43,858 (0%) | 0% | 0 | Ordinary Shares | |
| Geoffrey S. Martha | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 100,000 | 100,000 | - | - | Performance Share Unit | |
| Geoffrey S. Martha | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 295,680 | 295,680 | - | - | Stock Option (Right to Buy) | |
| Geoffrey S. Martha | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 40,000 | 184,120 (0%) | 0% | 0 | Ordinary Shares | |
| Jennifer M. Kirk | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 6,326 | 27,842 (0%) | 0% | 0 | Ordinary Shares | |
| Jennifer M. Kirk | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 1,540 | 1,540 | - | - | Stock Option (Right to Buy) | |
| Jennifer M. Kirk | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 3,125 | 3,125 | - | - | Performance Share Unit | |
| Jennifer M. Kirk | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 7,813 | 7,813 | - | - | Performance Share Unit | |
| Jennifer M. Kirk | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 7,813 | 21,516 (0%) | 0% | 0 | Ordinary Shares | |
| Sean Salmon | EVP & President Cardiovascular | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 35,938 | 35,938 | - | - | Performance Share Unit | |
| Sean Salmon | EVP & President Cardiovascular | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 14,375 | 63,084 (0%) | 0% | 0 | Ordinary Shares | |
| Sean Salmon | EVP & President Cardiovascular | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 106,260 | 106,260 | - | - | Stock Option (Right to Buy) | |
| Michael Marinaro | EVP & President, Surgical OU | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 13,750 | 42,131 (0%) | 0% | 0 | Ordinary Shares | |
| Michael Marinaro | EVP & President, Surgical OU | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jul 2024 | 34,375 | 34,375 | - | - | Performance Share Unit | |
| Michael Marinaro | EVP & President, Surgical OU | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 101,640 | 101,640 | - | - | Stock Option (Right to Buy) | |
| Matthew R. Walter | SVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 19,063 | 19,063 | - | - | Performance Share Unit | |
| Matthew R. Walter | SVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 56,364 | 56,364 | - | - | Stock Option (Right to Buy) | |
| Matthew R. Walter | SVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 7,625 | 25,205 (0%) | 0% | 0 | Ordinary Shares | |
| Matthew R. Walter | SVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 62.76 per share. | 18 Jul 2024 | 492 | 17,580 (0%) | 0% | 62.8 | 30,878 | Ordinary Shares |
| Matthew R. Walter | SVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jul 2024 | 492 | 0 | - | - | Stock Option (Right to Buy) | |
| Geoffrey S. Martha | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 83.82 per share. | 07 Jun 2024 | 1,594 | 143,348 (0%) | 0% | 83.8 | 133,609 | Ordinary Shares |
| Geoffrey S. Martha | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2024 | 1,594 | 0 | - | - | Stock Option (Right to Buy) | |
| Geoffrey S. Martha | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2024 | 17,519 | 1,594 | - | - | Stock Option (Right to Buy) | |
| Geoffrey S. Martha | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 62.76 per share. | 07 Jun 2024 | 17,519 | 160,867 (0%) | 0% | 62.8 | 1,099,492 | Ordinary Shares |
| Geoffrey S. Martha | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 83.76 per share. | 07 Jun 2024 | 17,519 | 144,942 (0%) | 0% | 83.8 | 1,467,391 | Ordinary Shares |
| Geoffrey S. Martha | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 62.76 per share. | 07 Jun 2024 | 1,594 | 162,461 (0%) | 0% | 62.8 | 100,039 | Ordinary Shares |
| Craig Arnold | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.89 per share. | 01 May 2024 | 192 | 38,275 (0%) | 0% | 80.9 | 15,531 | Ordinary Shares |
| Denise M. O'Leary | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.89 per share. | 01 May 2024 | 192 | 77,057 (0%) | 0% | 80.9 | 15,531 | Ordinary Shares |
| Kendall J. Powell | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.89 per share. | 01 May 2024 | 192 | 45,843 (0%) | 0% | 80.9 | 15,531 | Ordinary Shares |
| Lidia L. Fonseca | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.89 per share. | 01 May 2024 | 162 | 3,682 (0%) | 0% | 80.9 | 13,104 | Ordinary Shares |
| Randall J. Hogan | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.89 per share. | 01 May 2024 | 192 | 45,088 (0%) | 0% | 80.9 | 15,531 | Ordinary Shares |
| Scott C. Donnelly | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.89 per share. | 01 May 2024 | 192 | 19,604 (0%) | 0% | 80.9 | 15,531 | Ordinary Shares |
| Kevin E. Lofton | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.89 per share. | 01 May 2024 | 192 | 6,230 (0%) | 0% | 80.9 | 15,531 | Ordinary Shares |
| Elizabeth G. Nabel | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.89 per share. | 01 May 2024 | 192 | 15,674 (0%) | 0% | 80.9 | 15,531 | Ordinary Shares |
| Andrea J. Goldsmith | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.89 per share. | 01 May 2024 | 192 | 8,306 (0%) | 0% | 80.9 | 15,531 | Ordinary Shares |
| Craig Arnold | Director | Grant, award, or other acquisition of securities at price $ 80.86 per share. | 29 Apr 2024 | 2,165 | 38,467 (0%) | 0% | 80.9 | 175,062 | Ordinary Shares |
| Denise M. O'Leary | Director | Grant, award, or other acquisition of securities at price $ 80.86 per share. | 29 Apr 2024 | 2,165 | 77,249 (0%) | 0% | 80.9 | 175,062 | Ordinary Shares |
| Kendall J. Powell | Director | Grant, award, or other acquisition of securities at price $ 80.86 per share. | 29 Apr 2024 | 2,165 | 46,035 (0%) | 0% | 80.9 | 175,062 | Ordinary Shares |
| Lidia L. Fonseca | Director | Grant, award, or other acquisition of securities at price $ 80.86 per share. | 29 Apr 2024 | 2,165 | 3,844 (0%) | 0% | 80.9 | 175,062 | Ordinary Shares |
| Randall J. Hogan | Director | Grant, award, or other acquisition of securities at price $ 80.86 per share. | 29 Apr 2024 | 2,165 | 45,280 (0%) | 0% | 80.9 | 175,062 | Ordinary Shares |
| Scott C. Donnelly | Director | Grant, award, or other acquisition of securities at price $ 80.86 per share. | 29 Apr 2024 | 2,165 | 19,796 (0%) | 0% | 80.9 | 175,062 | Ordinary Shares |
| Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 80.86 per share. | 29 Apr 2024 | 2,165 | 6,422 (0%) | 0% | 80.9 | 175,062 | Ordinary Shares |
| Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 80.86 per share. | 29 Apr 2024 | 2,165 | 15,866 (0%) | 0% | 80.9 | 175,062 | Ordinary Shares |
| Andrea J. Goldsmith | Director | Grant, award, or other acquisition of securities at price $ 80.86 per share. | 29 Apr 2024 | 2,165 | 8,498 (0%) | 0% | 80.9 | 175,062 | Ordinary Shares |
| Gregory P. Lewis | Director | Grant, award, or other acquisition of securities at price $ 80.86 per share. | 29 Apr 2024 | 1,821 | 1,821 (0%) | 0% | 80.9 | 147,246 | Ordinary Shares |
| Michael Marinaro | EVP & President, Surgical OU | Sale of securities on an exchange or to another person at price $ 83.14 per share. | 08 Apr 2024 | 854 | 27,925 (0%) | 0% | 83.1 | 71,002 | Ordinary Shares |
| Michael Marinaro | EVP & President, Surgical OU | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.60 per share. | 05 Mar 2024 | 563 | 28,779 (0%) | 0% | 83.6 | 47,067 | Ordinary Shares |
| Sean Salmon | EVP & President Cardiovascular | Sale of securities on an exchange or to another person at price $ 85.12 per share. | 21 Feb 2024 | 16,035 | 48,289 (0%) | 0% | 85.1 | 1,364,899 | Ordinary Shares |
| Salmon Sean | EVP & President Cardiovascular | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2024 | 1,594 | 13,066 | - | - | Stock Option (Right to Buy) | |
| Sean Salmon | EVP & President Cardiovascular | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2024 | 16,035 | 0 | - | - | Stock Option (Right to Buy) | |
| Sean Salmon | EVP & President Cardiovascular | Sale of securities on an exchange or to another person at price $ 85.06 per share. | 21 Feb 2024 | 1,594 | 77,390 (0%) | 0% | 85.1 | 135,586 | Ordinary Shares |
| Salmon Sean | EVP & President Cardiovascular | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2024 | 13,066 | 0 | - | - | Stock Option (Right to Buy) | |
| Salmon Sean | EVP & President Cardiovascular | Exercise or conversion of derivative security received from the company (such as an option) at price $ 62.76 per share. | 21 Feb 2024 | 13,066 | 62,949 (0%) | 0% | 62.8 | 820,022 | Ordinary Shares |
| Salmon Sean | EVP & President Cardiovascular | Sale of securities on an exchange or to another person at price $ 85.15 per share. | 21 Feb 2024 | 13,066 | 64,324 (0%) | 0% | 85.2 | 1,112,570 | Ordinary Shares |
| Salmon Sean | EVP & President Cardiovascular | Exercise or conversion of derivative security received from the company (such as an option) at price $ 62.76 per share. | 21 Feb 2024 | 1,594 | 49,833 (0%) | 0% | 62.8 | 100,039 | Ordinary Shares |
| Sean Salmon | EVP & President Cardiovascular | Exercise or conversion of derivative security received from the company (such as an option) at price $ 74.84 per share. | 21 Feb 2024 | 16,035 | 78,984 (0%) | 0% | 74.8 | 1,200,059 | Ordinary Shares |
| M. Jennifer Kirk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 88.09 per share. | 01 Feb 2024 | 1,159 | 13,208 (0%) | 0% | 88.1 | 102,096 | Ordinary Shares |
| Wall A. Brett | EVP & Pres Neuroscience | Sale of securities on an exchange or to another person at price $ 82.17 per share. | 19 Dec 2023 | 4,997 | 28,910 (0%) | 0% | 82.2 | 410,603 | Ordinary Shares |
| White Robert J. | EVP & Pres. Medical Surgical | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.27 per share. | 08 Dec 2023 | 369 | 48,410 (0%) | 0% | 79.3 | 29,251 | Ordinary Shares |
| K. Fong Ivan | EVP GENERAL COUNSEL & SECR | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.27 per share. | 08 Dec 2023 | 716 | 40,091 (0%) | 0% | 79.3 | 56,757 | Ordinary Shares |
| Ivan Fong K. | EVP GENERAL COUNSEL & SECR | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.35 per share. | 08 Dec 2023 | 1,952 | 39,201 (0%) | 0% | 79.3 | 154,891 | Ordinary Shares |
| Wall Brett A. | EVP & Pres Neuroscience | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.27 per share. | 08 Dec 2023 | 435 | 33,907 (0%) | 0% | 79.3 | 34,482 | Ordinary Shares |
| Sean Salmon | EVP & President Cardiovascular | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.27 per share. | 08 Dec 2023 | 435 | 48,103 (0%) | 0% | 79.3 | 34,482 | Ordinary Shares |
| Jennifer M. Kirk | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Oct 2023 | 1,695 | 1,695 | - | - | Stock Option (Right to Buy) | |
| Gregory L. Smith | EVP Global Ops & Supply Chain | Sale of securities on an exchange or to another person at price $ 83.84 per share. | 23 Aug 2023 | 10,000 | 46,723 (0%) | 0% | 83.8 | 838,400 | Ordinary Shares |
| Brett A. Wall | EVP & Pres Neuroscience | Sale of securities on an exchange or to another person at price $ 83.38 per share. | 14 Aug 2023 | 1,000 | 33,573 (0%) | 0% | 83.4 | 83,380 | Ordinary Shares |
| Geoffrey S. Martha | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2023 | 18,165 | 159,109 (0%) | 0% | 0 | Ordinary Shares | |
| Robert Ten Hoedt | EVP and Pres. Global Regions | Payment of exercise price or tax liability using portion of securities received from the company at price $ 84.49 per share. | 03 Aug 2023 | 4,051 | 52,748 (0%) | 0% | 84.5 | 342,269 | Ordinary Shares |
| Robert Ten Hoedt | EVP and Pres. Global Regions | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2023 | 4,251 | 56,799 (0%) | 0% | 0 | Ordinary Shares | |
| Robert Ten Hoedt | EVP and Pres. Global Regions | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2023 | 4,251 | 0 | - | - | Performance Share Units | |
| Jennifer M. Kirk | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2023 | 1,178 | 0 | - | - | Performance Share Units | |
| Jennifer M. Kirk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 84.49 per share. | 03 Aug 2023 | 361 | 14,193 (0%) | 0% | 84.5 | 30,501 | Ordinary Shares |
| Jennifer M. Kirk | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2023 | 1,178 | 14,554 (0%) | 0% | 0 | Ordinary Shares | |
| Robert J. White | EVP & Pres. Medical Surgical | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2023 | 5,813 | 52,030 (0%) | 0% | 0 | Ordinary Shares | |
| Robert J. White | EVP & Pres. Medical Surgical | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2023 | 5,813 | 0 | - | - | Performance Share Units | |
| Robert J. White | EVP & Pres. Medical Surgical | Payment of exercise price or tax liability using portion of securities received from the company at price $ 84.49 per share. | 03 Aug 2023 | 4,065 | 47,965 (0%) | 0% | 84.5 | 343,452 | Ordinary Shares |
| Sean Salmon | EVP & President Cardiovascular | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2023 | 5,604 | 0 | - | - | Performance Share Units | |
| Sean Salmon | EVP & President Cardiovascular | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2023 | 5,604 | 52,095 (0%) | 0% | 0 | Ordinary Shares | |
| Sean Salmon | EVP & President Cardiovascular | Payment of exercise price or tax liability using portion of securities received from the company at price $ 84.49 per share. | 03 Aug 2023 | 4,369 | 47,726 (0%) | 0% | 84.5 | 369,137 | Ordinary Shares |
| Michael Marinaro | EVP & President, Surgical OU | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2023 | 1,696 | 31,605 (0%) | 0% | 0 | Ordinary Shares | |
| Michael Marinaro | EVP & President, Surgical OU | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2023 | 1,696 | 0 | - | - | Performance Share Unit | |
| Michael Marinaro | EVP & President, Surgical OU | Sale of securities on an exchange or to another person at price $ 84.11 per share. | 03 Aug 2023 | 1,352 | 28,930 (0%) | 0% | 84.1 | 113,717 | Ordinary Shares |
| Michael Marinaro | EVP & President, Surgical OU | Payment of exercise price or tax liability using portion of securities received from the company at price $ 84.49 per share. | 03 Aug 2023 | 1,323 | 30,282 (0%) | 0% | 84.5 | 111,780 | Ordinary Shares |
| Gregory L. Smith | EVP Global Ops & Supply Chain | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2023 | 6,217 | 0 | - | - | Performance Share Units | |
| Gregory L. Smith | EVP Global Ops & Supply Chain | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2023 | 6,217 | 61,416 (0%) | 0% | 0 | Ordinary Shares | |
| Gregory L. Smith | EVP Global Ops & Supply Chain | Payment of exercise price or tax liability using portion of securities received from the company at price $ 84.49 per share. | 03 Aug 2023 | 4,693 | 56,723 (0%) | 0% | 84.5 | 396,512 | Ordinary Shares |
| Brett A. Wall | EVP & Pres Neuroscience | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2023 | 5,168 | 38,857 (0%) | 0% | 0 | Ordinary Shares | |
| Brett A. Wall | EVP & Pres Neuroscience | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2023 | 5,168 | 0 | - | - | Performance Share Units | |
| Brett A. Wall | EVP & Pres Neuroscience | Payment of exercise price or tax liability using portion of securities received from the company at price $ 84.49 per share. | 03 Aug 2023 | 4,284 | 34,573 (0%) | 0% | 84.5 | 361,955 | Ordinary Shares |
| Karen L. Parkhill | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 84.49 per share. | 03 Aug 2023 | 5,919 | 46,327 (0%) | 0% | 84.5 | 500,096 | Ordinary Shares |
| Karen L. Parkhill | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2023 | 7,105 | 52,246 (0%) | 0% | 0 | Ordinary Shares | |
| Karen L. Parkhill | EVP & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2023 | 7,105 | 0 | - | - | Performance Share Units | |
| Geoffrey S. Martha | Director, Chairman and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 84.49 per share. | 03 Aug 2023 | 17,965 | 141,144 (0%) | 0% | 84.5 | 1,517,863 | Ordinary Shares |
| Geoffrey S. Martha | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2023 | 18,165 | 0 | - | - | Performance Share Units | |
| Ivan K. Fong | EVP GENERAL COUNSEL & SECR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 7,977 | 40,807 (0%) | 0% | 0 | Ordinary Shares | |
| Ivan K. Fong | EVP GENERAL COUNSEL & SECR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 56,162 | 56,162 | - | - | Stock Option (Right to Buy) | |
| Ivan K. Fong | EVP GENERAL COUNSEL & SECR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 19,941 | 19,941 | - | - | Performance Share Units | |
| Gregory L. Smith | EVP Global Ops & Supply Chain | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 64,185 | 64,185 | - | - | Stock Option (Right to Buy) | |
| Gregory L. Smith | EVP Global Ops & Supply Chain | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 22,790 | 22,790 | - | - | Performance Share Units | |
| Gregory L. Smith | EVP Global Ops & Supply Chain | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 26,209 | 55,167 (0%) | 0% | 0 | Ordinary Shares | |
| Brett A. Wall | EVP & Pres Neuroscience | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 9,686 | 33,634 (0%) | 0% | 0 | Ordinary Shares | |
| Brett A. Wall | EVP & Pres Neuroscience | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2023 | 68,196 | 68,196 | - | - | Stock Option (Right to Buy) | |
| Brett A. Wall | EVP & Pres Neuroscience | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 24,214 | 24,214 | - | - | Performance Share Units | |
| Karen L. Parkhill | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 12,535 | 44,418 (0%) | 0% | 0 | Ordinary Shares | |
| Karen L. Parkhill | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 88,254 | 88,254 | - | - | Stock Option (Right to Buy) | |
| Karen L. Parkhill | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 31,336 | 31,336 | - | - | Performance Share Units | |
| Geoffrey S. Martha | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 85,461 | 85,461 | - | - | Performance Share Units | |
| Geoffrey S. Martha | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 240,691 | 481,382 | - | - | Stock Option (Right to Buy) | |
| Geoffrey S. Martha | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 34,185 | 139,097 (0%) | 0% | 0 | Ordinary Shares | |
| Robert Ten Hoedt | EVP and Pres. Global Regions | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 21,366 | 21,366 | - | - | Performance Share Units | |
| Robert Ten Hoedt | EVP and Pres. Global Regions | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 8,547 | 52,499 (0%) | 0% | 0 | Ordinary Shares | |
| Robert Ten Hoedt | EVP and Pres. Global Regions | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 60,173 | 60,173 | - | - | Stock Option (Right to Buy) | |
| Jennifer M. Kirk | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 20,058 | 20,058 | - | - | Stock Option (Right to Buy) | |
| Jennifer M. Kirk | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 2,849 | 13,376 (0%) | 0% | 0 | Ordinary Shares | |
| Jennifer M. Kirk | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 7,122 | 7,122 | - | - | Performance Share Units | |
| Robert J. White | EVP & Pres. Medical Surgical | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 9,116 | 46,156 (0%) | 0% | 0 | Ordinary Shares | |
| Robert J. White | EVP & Pres. Medical Surgical | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 22,790 | 22,790 | - | - | Performance Share Units | |
| Robert J. White | EVP & Pres. Medical Surgical | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 64,185 | 64,185 | - | - | Stock Option (Right to Buy) | |
| Sean Salmon | EVP & President Cardiovascular | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 9,686 | 46,290 (0%) | 0% | 0 | Ordinary Shares | |
| Sean Salmon | EVP & President Cardiovascular | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 68,196 | 68,196 | - | - | Stock Option (Right to Buy) | |
| Sean Salmon | EVP & President Cardiovascular | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 21,214 | 21,214 | - | - | Performance Share Units | |
| Michael Marinaro | EVP & President, Surgical OU | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 6,837 | 29,890 (0%) | 0% | 0 | Ordinary Shares | |
| Michael Marinaro | EVP & President, Surgical OU | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 48,139 | 48,139 | - | - | Stock Option (Right to Buy) | |
| Michael Marinaro | EVP & President, Surgical OU | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 17,093 | 17,093 | - | - | Performance Share Units | |
| Brett A. Wall | EVP & Pres Neuroscience | Sale of securities on an exchange or to another person at price $ 87.97 per share. | 14 Jul 2023 | 2,000 | 23,948 (0%) | 0% | 88.0 | 175,940 | Ordinary Shares |
| Robert Ten Hoedt | EVP and Pres. Global Regions | Sale of securities on an exchange or to another person at price $ 86.59 per share. | 10 Jul 2023 | 1,808 | 43,802 (0%) | 0% | 86.6 | 156,555 | Ordinary Shares |
| Robert Ten Hoedt | EVP and Pres. Global Regions | Exercise or conversion of derivative security received from the company (such as an option) at price $ 55.32 per share. | 10 Jul 2023 | 1,808 | 45,610 (0%) | 0% | 55.3 | 100,019 | Ordinary Shares |
| Robert Ten Hoedt | EVP and Pres. Global Regions | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2023 | 3,706 | 0 | - | - | Stock Option (Right to Buy) | |
| Robert Ten Hoedt | EVP and Pres. Global Regions | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2023 | 1,808 | 3,706 | - | - | Stock Option (Right to Buy) | |
| Robert Ten Hoedt | EVP and Pres. Global Regions | Exercise or conversion of derivative security received from the company (such as an option) at price $ 55.32 per share. | 10 Jul 2023 | 3,706 | 47,508 (0%) | 0% | 55.3 | 205,016 | Ordinary Shares |
| Robert Ten Hoedt | EVP and Pres. Global Regions | Sale of securities on an exchange or to another person at price $ 86.58 per share. | 10 Jul 2023 | 3,706 | 43,802 (0%) | 0% | 86.6 | 320,865 | Ordinary Shares |
| Craig Arnold | Director | Grant, award, or other acquisition of securities at price $ 90.68 per share. | 01 May 2023 | 1,930 | 36,405 (0%) | 0% | 90.7 | 175,012 | Ordinary Shares |
| Craig Arnold | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 90.23 per share. | 01 May 2023 | 169 | 36,236 (0%) | 0% | 90.2 | 15,249 | Ordinary Shares |
| Denise M. O'Leary | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 90.23 per share. | 01 May 2023 | 169 | 73,838 (0%) | 0% | 90.2 | 15,249 | Ordinary Shares |
| Denise M. O'Leary | Director | Grant, award, or other acquisition of securities at price $ 90.68 per share. | 01 May 2023 | 1,930 | 74,007 (0%) | 0% | 90.7 | 175,012 | Ordinary Shares |
| Kendall J. Powell | Director | Grant, award, or other acquisition of securities at price $ 90.68 per share. | 01 May 2023 | 1,930 | 40,161 (0%) | 0% | 90.7 | 175,012 | Ordinary Shares |
| Kendall J. Powell | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 90.23 per share. | 01 May 2023 | 169 | 39,992 (0%) | 0% | 90.2 | 15,249 | Ordinary Shares |
| Lidia L. Fonseca | Director | Grant, award, or other acquisition of securities at price $ 90.68 per share. | 01 May 2023 | 1,624 | 1,624 (0%) | 0% | 90.7 | 147,264 | Ordinary Shares |
| Randall J. Hogan | Director | Grant, award, or other acquisition of securities at price $ 90.68 per share. | 01 May 2023 | 1,930 | 6,133 (0%) | 0% | 90.7 | 175,012 | Ordinary Shares |
| Randall J. Hogan | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 90.23 per share. | 01 May 2023 | 169 | 5,964 (0%) | 0% | 90.2 | 15,249 | Ordinary Shares |
| Richard H. Anderson | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 90.23 per share. | 01 May 2023 | 169 | 113,023 (0%) | 0% | 90.2 | 15,249 | Ordinary Shares |
| Richard H. Anderson | Director | Grant, award, or other acquisition of securities at price $ 90.68 per share. | 01 May 2023 | 1,930 | 113,192 (0%) | 0% | 90.7 | 175,012 | Ordinary Shares |
| Scott C. Donnelly | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 90.23 per share. | 01 May 2023 | 169 | 16,576 (0%) | 0% | 90.2 | 15,249 | Ordinary Shares |
| Scott C. Donnelly | Director | Grant, award, or other acquisition of securities at price $ 90.68 per share. | 01 May 2023 | 1,930 | 16,745 (0%) | 0% | 90.7 | 175,012 | Ordinary Shares |
| Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 90.68 per share. | 01 May 2023 | 1,930 | 4,360 (0%) | 0% | 90.7 | 175,012 | Ordinary Shares |
| Kevin E. Lofton | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 90.23 per share. | 01 May 2023 | 169 | 4,191 (0%) | 0% | 90.2 | 15,249 | Ordinary Shares |
| Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 90.68 per share. | 01 May 2023 | 1,930 | 13,804 (0%) | 0% | 90.7 | 175,012 | Ordinary Shares |
| Elizabeth G. Nabel | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 90.23 per share. | 01 May 2023 | 169 | 13,635 (0%) | 0% | 90.2 | 15,249 | Ordinary Shares |
| Andrea J. Goldsmith | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 90.23 per share. | 01 May 2023 | 169 | 6,267 (0%) | 0% | 90.2 | 15,249 | Ordinary Shares |
| Andrea J. Goldsmith | Director | Grant, award, or other acquisition of securities at price $ 90.68 per share. | 01 May 2023 | 1,930 | 6,436 (0%) | 0% | 90.7 | 175,012 | Ordinary Shares |
| Gregory L. Smith | EVP Global Ops & Supply Chain | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.72 per share. | 18 Apr 2023 | 74 | 28,882 (0%) | 0% | 80.7 | 5,973 | Ordinary Shares |
| Gregory L. Smith | EVP Global Ops & Supply Chain | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.27 per share. | 05 Apr 2023 | 6,866 | 28,579 (0%) | 0% | 80.3 | 551,134 | Ordinary Shares |
| Jennifer M. Kirk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 85.77 per share. | 01 Feb 2023 | 672 | 10,115 (0%) | 0% | 85.8 | 57,637 | Ordinary Shares |
| Sean Salmon | EVP & President Cardiovascular | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2022 | 14,823 | 0 | - | - | Stock Option (Right to Buy) | |
| Sean Salmon | EVP & President Cardiovascular | Exercise or conversion of derivative security received from the company (such as an option) at price $ 55.32 per share. | 13 Dec 2022 | 14,823 | 52,719 (0%) | 0% | 55.3 | 820,008 | Ordinary Shares |
| Sean Salmon | EVP & President Cardiovascular | Exercise or conversion of derivative security received from the company (such as an option) at price $ 55.32 per share. | 13 Dec 2022 | 1,808 | 37,896 (0%) | 0% | 55.3 | 100,019 | Ordinary Shares |
| Sean Salmon | EVP & President Cardiovascular | Sale of securities on an exchange or to another person at price $ 80.50 per share. | 13 Dec 2022 | 16,631 | 36,088 (0%) | 0% | 80.5 | 1,338,736 | Ordinary Shares |
| Sean Salmon | EVP & President Cardiovascular | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2022 | 1,808 | 0 | - | - | Stock Option (Right to Buy) | |
| Ivan K. Fong | EVP GENERAL COUNSEL & SECR | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.59 per share. | 09 Dec 2022 | 5,206 | 32,830 (0%) | 0% | 78.6 | 409,140 | Ordinary Shares |
| Sean Salmon | EVP & President Cardiovascular | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.04 per share. | 07 Dec 2022 | 300 | 36,088 (0%) | 0% | 79.0 | 23,712 | Ordinary Shares |
| Brett A. Wall | EVP & Pres Neuroscience | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.04 per share. | 07 Dec 2022 | 337 | 25,470 (0%) | 0% | 79.0 | 26,636 | Ordinary Shares |
| Robert J. White | EVP & Pres. Medical Surgical | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.04 per share. | 07 Dec 2022 | 348 | 36,186 (0%) | 0% | 79.0 | 27,506 | Ordinary Shares |
| Robert Ten Hoedt | EVP and Pres. Global Regions | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Oct 2022 | 2,404 | 0 | - | - | Stock Option (Right to Buy) | |
| Robert Ten Hoedt | EVP and Pres. Global Regions | Sale of securities on an exchange or to another person at price $ 81.54 per share. | 14 Oct 2022 | 2,404 | 43,483 (0%) | 0% | 81.5 | 196,015 | Ordinary Shares |
| Robert Ten Hoedt | EVP and Pres. Global Regions | Exercise or conversion of derivative security received from the company (such as an option) at price $ 41.60 per share. | 14 Oct 2022 | 2,404 | 45,887 (0%) | 0% | 41.6 | 100,006 | Ordinary Shares |
| Ivan K. Fong | EVP GENERAL COUNSEL & SECR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 54,849 | 54,849 | - | - | Stock Option (Right to Buy) | |
| Ivan K. Fong | EVP GENERAL COUNSEL & SECR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 6,941 | 37,722 (0%) | 0% | 0 | Ordinary Shares | |
| Ivan K. Fong | EVP GENERAL COUNSEL & SECR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 17,351 | 17,351 | - | - | Performance Share Units | |
| Brett A. Wall | EVP & Pres Neuroscience | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 18,802 | 18,802 | - | - | Performance Share Units | |
| Brett A. Wall | EVP & Pres Neuroscience | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 59,433 | 59,433 | - | - | Stock Option (Right to Buy) | |
| Brett A. Wall | EVP & Pres Neuroscience | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 7,521 | 25,646 (0%) | 0% | 0 | Ordinary Shares | |
| Carol A. Surface | EVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 12,893 | 12,893 | - | - | Performance Share Units | |
| Carol A. Surface | EVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 40,754 | 40,754 | - | - | Stock Option (Right to Buy) | |
| Carol A. Surface | EVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 5,157 | 26,193 (0%) | 0% | 0 | Ordinary Shares | |
| Karen L. Parkhill | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 10,744 | 30,962 (0%) | 0% | 0 | Ordinary Shares | |
| Karen L. Parkhill | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 84,905 | 84,905 | - | - | Stock Option (Right to Buy) | |
| Karen L. Parkhill | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 26,859 | 26,859 | - | - | Performance Share Units | |
| Geoffrey S. Martha | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 224,996 | 224,996 | - | - | Stock Option (Right to Buy) | |
| Geoffrey S. Martha | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 28,471 | 102,497 (0%) | 0% | 0 | Ordinary Shares | |
| Geoffrey S. Martha | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 71,176 | 71,176 | - | - | Performance Share Units | |
| Robert Ten Hoedt | EVP & President EMEA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 7,306 | 43,483 (0%) | 0% | 0 | Ordinary Shares | |
| Robert Ten Hoedt | EVP & President EMEA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 18,264 | 18,264 | - | - | Performance Share Units | |
| Robert Ten Hoedt | EVP & President EMEA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 57,735 | 57,735 | - | - | Stock Option (Right to Buy) | |
| Jennifer M. Kirk | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 5,909 | 5,909 | - | - | Performance Share Units | |
| Jennifer M. Kirk | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 2,364 | 10,630 (0%) | 0% | 0 | Ordinary Shares | |
| Jennifer M. Kirk | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 18,679 | 18,679 | - | - | Stock Option (Right to Buy) | |
| Jennifer M. Kirk | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 1,416 | 1,416 | - | - | Stock Option (Right to Buy) | |
| Robert J. White | EVP & Pres. Medical Surgical | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 67,924 | 67,924 | - | - | Stock Option (Right to Buy) | |
| Robert J. White | EVP & Pres. Medical Surgical | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 21,487 | 21,487 | - | - | Performance Share Units | |
| Robert J. White | EVP & Pres. Medical Surgical | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 8,595 | 36,351 (0%) | 0% | 0 | Ordinary Shares | |
| Sean Salmon | EVP & President Cardiovascular | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 8,595 | 36,214 (0%) | 0% | 0 | Ordinary Shares | |
| Sean Salmon | EVP & President Cardiovascular | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 67,924 | 67,924 | - | - | Stock Option (Right to Buy) | |
| Sean Salmon | EVP & President Cardiovascular | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 21,487 | 21,487 | - | - | Performance Share Units | |
| Brett A. Wall | EVP & Pres Neuroscience | Sale or transfer of securities back to the company at price $ 0.00 per share. | 29 Jul 2022 | 7,493 | 18,125 (0%) | 0% | 0 | Ordinary Shares | |
| Carol A. Surface | EVP, Chief HR Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 29 Jul 2022 | 7,920 | 21,036 (0%) | 0% | 0 | Ordinary Shares | |
| Karen L. Parkhill | EVP & Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 29 Jul 2022 | 15,151 | 20,218 (0%) | 0% | 0 | Ordinary Shares | |
| Geoffrey S. Martha | Director, Chairman and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 29 Jul 2022 | 23,410 | 74,026 (0%) | 0% | 0 | Ordinary Shares | |
| Robert Ten Hoedt | EVP & President EMEA | Sale or transfer of securities back to the company at price $ 0.00 per share. | 29 Jul 2022 | 9,641 | 36,177 (0%) | 0% | 0 | Ordinary Shares | |
| Robert J. White | EVP & Pres. Medical Surgical | Sale or transfer of securities back to the company at price $ 0.00 per share. | 29 Jul 2022 | 12,397 | 27,756 (0%) | 0% | 0 | Ordinary Shares | |
| John R. Liddicoat | EVP & President of Americas | Sale or transfer of securities back to the company at price $ 0.00 per share. | 29 Jul 2022 | 6,543 | 37,374 (0%) | 0% | 0 | Ordinary Shares | |
| Sean Salmon | EVP & President Cardiovascular | Sale or transfer of securities back to the company at price $ 0.00 per share. | 29 Jul 2022 | 5,808 | 27,619 (0%) | 0% | 0 | Ordinary Shares | |
| Craig Arnold | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2022 | 1,697 | 34,681 (0%) | 0% | 0 | Ordinary Shares | |
| Craig Arnold | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.11 per share. | 02 May 2022 | 262 | 34,419 (0%) | 0% | 103.1 | 27,015 | Ordinary Shares |
| Denise M. O'Leary | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2022 | 1,697 | 71,179 (0%) | 0% | 0 | Ordinary Shares | |
| Denise M. O'Leary | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.11 per share. | 02 May 2022 | 262 | 70,917 (0%) | 0% | 103.1 | 27,015 | Ordinary Shares |
| Kendall J. Powell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2022 | 1,697 | 37,679 (0%) | 0% | 0 | Ordinary Shares | |
| Kendall J. Powell | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.11 per share. | 02 May 2022 | 262 | 37,417 (0%) | 0% | 103.1 | 27,015 | Ordinary Shares |
| Randall J. Hogan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2022 | 1,697 | 4,409 (0%) | 0% | 0 | Ordinary Shares | |
| Randall J. Hogan | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.11 per share. | 02 May 2022 | 262 | 4,147 (0%) | 0% | 103.1 | 27,015 | Ordinary Shares |
| Richard H. Anderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2022 | 1,697 | 110,444 (0%) | 0% | 0 | Ordinary Shares | |
| Richard H. Anderson | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.11 per share. | 02 May 2022 | 262 | 110,182 (0%) | 0% | 103.1 | 27,015 | Ordinary Shares |
| Scott C. Donnelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2022 | 1,697 | 15,124 (0%) | 0% | 0 | Ordinary Shares | |
| Scott C. Donnelly | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.11 per share. | 02 May 2022 | 262 | 14,862 (0%) | 0% | 103.1 | 27,015 | Ordinary Shares |
| Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2022 | 1,697 | 2,535 (0%) | 0% | 0 | Ordinary Shares | |
| Kevin E. Lofton | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.11 per share. | 02 May 2022 | 161 | 2,374 (0%) | 0% | 103.1 | 16,601 | Ordinary Shares |
| Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2022 | 1,697 | 12,080 (0%) | 0% | 0 | Ordinary Shares | |
| Elizabeth G. Nabel | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.11 per share. | 02 May 2022 | 262 | 11,818 (0%) | 0% | 103.1 | 27,015 | Ordinary Shares |
| Andrea J. Goldsmith | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.11 per share. | 02 May 2022 | 262 | 4,450 (0%) | 0% | 103.1 | 27,015 | Ordinary Shares |
| Andrea J. Goldsmith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2022 | 1,697 | 4,712 (0%) | 0% | 0 | Ordinary Shares | |
| Karen L. Parkhill | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 110.00 per share. | 18 Mar 2022 | 682 | 34,946 (0%) | 0% | 110 | 75,020 | Ordinary Shares |
| Carol A. Surface | SVP, Chief HR Officer | Sale of securities on an exchange or to another person at price $ 105.30 per share. | 11 Mar 2022 | 6,000 | 28,502 (0%) | 0% | 105.3 | 631,800 | Ordinary Shares |
| Ivan K. Fong | EVP GENERAL COUNSEL & SECR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 6,237 | 6,237 (0%) | 0% | 0 | Ordinary Shares | |
| Ivan K. Fong | EVP GENERAL COUNSEL & SECR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 21,238 | 21,238 | - | - | Performance Share Units | |
| Ivan K. Fong | EVP GENERAL COUNSEL & SECR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 145,852 | 145,852 | - | - | Stock Option (Right to Buy) | |
| Ivan K. Fong | EVP GENERAL COUNSEL & SECR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 15,591 | 15,591 | - | - | Performance Share Units | |
| Ivan K. Fong | EVP GENERAL COUNSEL & SECR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 50,476 | 50,476 | - | - | Stock Option (Right to Buy) | |
| Ivan K. Fong | EVP GENERAL COUNSEL & SECR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 24,134 | 30,371 (0%) | 0% | 0 | Ordinary Shares | |
| Jennifer M. Kirk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.59 per share. | 01 Feb 2022 | 636 | 7,934 (0%) | 0% | 103.6 | 65,883 | Ordinary Shares |
| Robert J. White | EVP & Pres. Medical Surgical | Sale of securities on an exchange or to another person at price $ 102.04 per share. | 23 Dec 2021 | 7,218 | 39,430 (0%) | 0% | 102.0 | 736,525 | Ordinary Shares |
| Richard H. Anderson | Director | Purchase of securities on an exchange or from another person at price $ 103.26 per share. | 16 Dec 2021 | 5,010 | 108,374 (0%) | 0% | 103.3 | 517,333 | Ordinary Shares |
| Sean Salmon | EVP & Pres Diabetes/Cardiovasc | Payment of exercise price or tax liability using portion of securities received from the company at price $ 104.94 per share. | 15 Dec 2021 | 89 | 33,083 (0%) | 0% | 104.9 | 9,340 | Ordinary Shares |
| Karen L. Parkhill | EVP & Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 06 Dec 2021 | 49,859 | 0 (0%) | 0% | 0 | Ordinary Shares | |
| Karen L. Parkhill | EVP & Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 06 Dec 2021 | 49,859 | 49,859 (0%) | 0% | 0 | Ordinary Shares | |
| Karen L. Parkhill | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 110.00 per share. | 06 Dec 2021 | 682 | 35,446 (0%) | 0% | 110 | 75,020 | Ordinary Shares |
| Richard E. Kuntz | SVP & Chief Medical & Science | Payment of exercise price or tax liability using portion of securities received from the company at price $ 122.98 per share. | 05 Nov 2021 | 209 | 74,945 (0%) | 0% | 123.0 | 25,703 | Ordinary Shares |
| Brett A. Wall | EVP & Pres Neuroscience | Payment of exercise price or tax liability using portion of securities received from the company at price $ 122.98 per share. | 05 Nov 2021 | 238 | 25,251 (0%) | 0% | 123.0 | 29,269 | Ordinary Shares |
| Bradley E. Lerman | SVP General Counsel & Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 122.98 per share. | 05 Nov 2021 | 250 | 48,635 (0%) | 0% | 123.0 | 30,745 | Ordinary Shares |
| Robert J. White | EVP & Pres. Medical Surgical | Payment of exercise price or tax liability using portion of securities received from the company at price $ 122.98 per share. | 05 Nov 2021 | 246 | 46,648 (0%) | 0% | 123.0 | 30,253 | Ordinary Shares |
| John R. Liddicoat | EVP & President of Americas | Payment of exercise price or tax liability using portion of securities received from the company at price $ 122.98 per share. | 05 Nov 2021 | 139 | 42,998 (0%) | 0% | 123.0 | 17,094 | Ordinary Shares |
| Sean Salmon | EVP & Pres Diabetes/Cardiovasc | Payment of exercise price or tax liability using portion of securities received from the company at price $ 122.98 per share. | 05 Nov 2021 | 245 | 33,172 (0%) | 0% | 123.0 | 30,130 | Ordinary Shares |
| Robert Ten Hoedt | EVP & President EMEA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2021 | 6,670 | 6,670 | - | - | Stock Option (Right to Buy) | |
| Robert Ten Hoedt | EVP & President EMEA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2021 | 2,080 | 2,080 | - | - | Performance Share Units | |
| Robert Ten Hoedt | EVP & President EMEA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2021 | 832 | 45,418 (0%) | 0% | 0 | Ordinary Shares | |
| Karen L. Parkhill | EVP & Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 06 Oct 2021 | 37,859 | 37,859 (0%) | 0% | 0 | Ordinary Shares | |
| Karen L. Parkhill | EVP & Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 06 Oct 2021 | 12,000 | 49,859 (0%) | 0% | 0 | Ordinary Shares | |
| Karen L. Parkhill | EVP & Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 06 Oct 2021 | 12,000 | 35,974 (0%) | 0% | 0 | Ordinary Shares | |
| Karen L. Parkhill | EVP & Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 06 Oct 2021 | 37,859 | 47,974 (0%) | 0% | 0 | Ordinary Shares | |
| Bradley E. Lerman | SVP General Counsel & Corp Sec | Sale of securities on an exchange or to another person at price $ 126.58 per share. | 30 Sep 2021 | 49,147 | 48,763 (0%) | 0% | 126.6 | 6,221,027 | Ordinary Shares |
| Bradley E. Lerman | SVP General Counsel & Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2021 | 49,147 | 0 | - | - | Stock Option (Right to Buy) | |
| Bradley E. Lerman | SVP General Counsel & Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 78.00 per share. | 30 Sep 2021 | 49,147 | 97,910 (0%) | 0% | 78 | 3,833,466 | Ordinary Shares |
| Bradley E. Lerman | SVP General Counsel & Corp Sec | Sale of securities on an exchange or to another person at price $ 134.17 per share. | 31 Aug 2021 | 50,775 | 48,763 (0%) | 0% | 134.2 | 6,812,482 | Ordinary Shares |
| Bradley E. Lerman | SVP General Counsel & Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2021 | 50,775 | 0 | - | - | Stock Option (Right to Buy) | |
| Bradley E. Lerman | SVP General Counsel & Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 74.84 per share. | 31 Aug 2021 | 50,775 | 99,538 (0%) | 0% | 74.8 | 3,800,001 | Ordinary Shares |
| Geoffrey S. Martha | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 55.32 per share. | 25 Aug 2021 | 1,481 | 97,317 (0%) | 0% | 55.3 | 81,929 | Ordinary Shares |
| Geoffrey S. Martha | Director, CEO | Sale of securities on an exchange or to another person at price $ 132.67 per share. | 25 Aug 2021 | 1,481 | 95,836 (0%) | 0% | 132.7 | 196,484 | Ordinary Shares |
| Geoffrey S. Martha | Director, CEO | Sale of securities on an exchange or to another person at price $ 132.67 per share. | 25 Aug 2021 | 10,100 | 95,836 (0%) | 0% | 132.7 | 1,339,967 | Ordinary Shares |
| Geoffrey S. Martha | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2021 | 1,481 | 0 | - | - | Stock Option (Right to Buy) | |
| Geoffrey S. Martha | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2021 | 10,100 | 17,519 | - | - | Stock Option (Right to Buy) | |
| Geoffrey S. Martha | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 62.76 per share. | 25 Aug 2021 | 10,100 | 105,936 (0%) | 0% | 62.8 | 633,876 | Ordinary Shares |
| Sean Salmon | EVP & Pres Diabetes/Cardiovasc | Sale of securities on an exchange or to another person at price $ 134.08 per share. | 25 Aug 2021 | 21,129 | 33,329 (0%) | 0% | 134.1 | 2,832,976 | Ordinary Shares |
| Sean Salmon | EVP & Pres Diabetes/Cardiovasc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2021 | 4,713 | 0 | - | - | Stock Option (Right to Buy) | |
| Sean Salmon | EVP & Pres Diabetes/Cardiovasc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2021 | 2,577 | 0 | - | - | Stock Option (Right to Buy) | |
| Sean Salmon | EVP & Pres Diabetes/Cardiovasc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2021 | 21,129 | 0 | - | - | Stock Option (Right to Buy) | |
| Sean Salmon | EVP & Pres Diabetes/Cardiovasc | Sale of securities on an exchange or to another person at price $ 134.09 per share. | 25 Aug 2021 | 7,290 | 33,329 (0%) | 0% | 134.1 | 977,516 | Ordinary Shares |
| Sean Salmon | EVP & Pres Diabetes/Cardiovasc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.20 per share. | 25 Aug 2021 | 4,713 | 40,619 (0%) | 0% | 38.2 | 180,037 | Ordinary Shares |
| Sean Salmon | EVP & Pres Diabetes/Cardiovasc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.81 per share. | 25 Aug 2021 | 2,577 | 35,906 (0%) | 0% | 38.8 | 100,013 | Ordinary Shares |
| Sean Salmon | EVP & Pres Diabetes/Cardiovasc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.81 per share. | 25 Aug 2021 | 21,129 | 54,458 (0%) | 0% | 38.8 | 820,016 | Ordinary Shares |
| Richard E. Kuntz | SVP & Chief Medical & Science | Payment of exercise price or tax liability using portion of securities received from the company at price $ 131.31 per share. | 02 Aug 2021 | 4,905 | 69,886 (0%) | 0% | 131.3 | 644,076 | Ordinary Shares |
| Richard E. Kuntz | SVP & Chief Medical & Science | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 12,571 | 12,571 | - | - | Performance Share Units | |
| Richard E. Kuntz | SVP & Chief Medical & Science | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 1,085 | 1,085 | - | - | Stock Option (Right to Buy) | |
| Richard E. Kuntz | SVP & Chief Medical & Science | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 42,961 | 42,961 | - | - | Stock Option (Right to Buy) | |
| Richard E. Kuntz | SVP & Chief Medical & Science | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 5,029 | 74,915 (0%) | 0% | 0 | Ordinary Shares | |
| Brett A. Wall | EVP & Pres Neuroscience | Payment of exercise price or tax liability using portion of securities received from the company at price $ 131.31 per share. | 02 Aug 2021 | 1,482 | 20,062 (0%) | 0% | 131.3 | 194,601 | Ordinary Shares |
| Brett A. Wall | EVP & Pres Neuroscience | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 13,333 | 13,333 | - | - | Performance Share Units | |
| Brett A. Wall | EVP & Pres Neuroscience | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 1,085 | 1,085 | - | - | Stock Option (Right to Buy) | |
| Brett A. Wall | EVP & Pres Neuroscience | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 45,565 | 45,565 | - | - | Stock Option (Right to Buy) | |
| Brett A. Wall | EVP & Pres Neuroscience | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 5,333 | 25,395 (0%) | 0% | 0 | Ordinary Shares | |
| Carol A. Surface | SVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 31,245 | 31,245 | - | - | Stock Option (Right to Buy) | |
| Carol A. Surface | SVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 3,657 | 34,327 (0%) | 0% | 0 | Ordinary Shares | |
| Carol A. Surface | SVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 131.31 per share. | 02 Aug 2021 | 3,997 | 30,670 (0%) | 0% | 131.3 | 524,846 | Ordinary Shares |
| Carol A. Surface | SVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 9,143 | 9,143 | - | - | Performance Share Units | |
| Carol A. Surface | SVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 1,085 | 1,085 | - | - | Stock Option (Right to Buy) | |
| Karen L. Parkhill | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 7,162 | 85,833 (0%) | 0% | 0 | Ordinary Shares | |
| Karen L. Parkhill | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 131.31 per share. | 02 Aug 2021 | 6,839 | 78,671 (0%) | 0% | 131.3 | 898,029 | Ordinary Shares |
| Karen L. Parkhill | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 17,904 | 17,904 | - | - | Performance Share Units | |
| Karen L. Parkhill | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 1,085 | 1,085 | - | - | Stock Option (Right to Buy) | |
| Karen L. Parkhill | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 61,187 | 61,187 | - | - | Stock Option (Right to Buy) | |
| Bradley E. Lerman | SVP General Counsel & Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 131.31 per share. | 02 Aug 2021 | 5,450 | 42,744 (0%) | 0% | 131.3 | 715,640 | Ordinary Shares |
| Bradley E. Lerman | SVP General Counsel & Corp Sec | Sale of securities on an exchange or to another person at price $ 131.52 per share. | 02 Aug 2021 | 4,000 | 48,194 (0%) | 0% | 131.5 | 526,080 | Ordinary Shares |
| Bradley E. Lerman | SVP General Counsel & Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 15,047 | 15,047 | - | - | Performance Share Units | |
| Bradley E. Lerman | SVP General Counsel & Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 1,085 | 1,085 | - | - | Stock Option (Right to Buy) | |
| Bradley E. Lerman | SVP General Counsel & Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 51,423 | 51,423 | - | - | Stock Option (Right to Buy) | |
| Bradley E. Lerman | SVP General Counsel & Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 6,019 | 48,763 (0%) | 0% | 0 | Ordinary Shares | |
| Geoffrey S. Martha | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 19,047 | 95,836 (0%) | 0% | 0 | Ordinary Shares | |
| Geoffrey S. Martha | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 131.31 per share. | 02 Aug 2021 | 5,450 | 76,789 (0%) | 0% | 131.3 | 715,640 | Ordinary Shares |
| Geoffrey S. Martha | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 162,731 | 162,731 | - | - | Stock Option (Right to Buy) | |
| Geoffrey S. Martha | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 47,616 | 47,616 | - | - | Performance Share Units | |
| Robert Ten Hoedt | EVP & President EMEA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 4,419 | 44,489 (0%) | 0% | 0 | Ordinary Shares | |
| Robert Ten Hoedt | EVP & President EMEA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 37,754 | 37,754 | - | - | Stock Option (Right to Buy) | |
| Robert Ten Hoedt | EVP & President EMEA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 1,085 | 1,085 | - | - | Stock Option (Right to Buy) | |
| Robert Ten Hoedt | EVP & President EMEA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 11,047 | 11,047 | - | - | Performance Share Units | |
| Robert Ten Hoedt | EVP & President EMEA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 131.31 per share. | 02 Aug 2021 | 3,908 | 40,070 (0%) | 0% | 131.3 | 513,159 | Ordinary Shares |
| Jennifer M. Kirk | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 9,764 | 9,764 | - | - | Stock Option (Right to Buy) | |
| Jennifer M. Kirk | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 1,085 | 1,085 | - | - | Stock Option (Right to Buy) | |
| Jennifer M. Kirk | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 2,857 | 2,857 | - | - | Performance Share Units | |
| Jennifer M. Kirk | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 1,143 | 8,387 (0%) | 0% | 0 | Ordinary Shares | |
| Robert J. White | EVP & Pres. Medical Surgical | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 52,074 | 52,074 | - | - | Stock Option (Right to Buy) | |
| Robert J. White | EVP & Pres. Medical Surgical | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 1,085 | 1,085 | - | - | Stock Option (Right to Buy) | |
| Robert J. White | EVP & Pres. Medical Surgical | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 6,095 | 46,769 (0%) | 0% | 0 | Ordinary Shares | |
| Robert J. White | EVP & Pres. Medical Surgical | Payment of exercise price or tax liability using portion of securities received from the company at price $ 131.31 per share. | 02 Aug 2021 | 4,897 | 40,674 (0%) | 0% | 131.3 | 643,025 | Ordinary Shares |
| Robert J. White | EVP & Pres. Medical Surgical | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 15,237 | 15,237 | - | - | Performance Share Units | |
| John R. Liddicoat | EVP & President of Americas | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 8,381 | 8,381 | - | - | Performance Share Units | |
| John R. Liddicoat | EVP & President of Americas | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 1,085 | 1,085 | - | - | Stock Option (Right to Buy) | |
| John R. Liddicoat | EVP & President of Americas | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 28,641 | 28,641 | - | - | Stock Option (Right to Buy) | |
| John R. Liddicoat | EVP & President of Americas | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 3,353 | 42,847 (0%) | 0% | 0 | Ordinary Shares | |
| John R. Liddicoat | EVP & President of Americas | Payment of exercise price or tax liability using portion of securities received from the company at price $ 131.31 per share. | 02 Aug 2021 | 3,258 | 39,494 (0%) | 0% | 131.3 | 427,808 | Ordinary Shares |
| Sean Salmon | EVP & Pres Diabetes/Cardiovasc | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 1,085 | 1,085 | - | - | Stock Option (Right to Buy) | |
| Sean Salmon | EVP & Pres Diabetes/Cardiovasc | Payment of exercise price or tax liability using portion of securities received from the company at price $ 131.31 per share. | 02 Aug 2021 | 2,272 | 27,843 (0%) | 0% | 131.3 | 298,336 | Ordinary Shares |
| Sean Salmon | EVP & Pres Diabetes/Cardiovasc | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 5,486 | 33,329 (0%) | 0% | 0 | Ordinary Shares | |
| Sean Salmon | EVP & Pres Diabetes/Cardiovasc | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 46,867 | 46,867 | - | - | Stock Option (Right to Buy) | |
| Sean Salmon | EVP & Pres Diabetes/Cardiovasc | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 13,714 | 13,714 | - | - | Performance Share Units | |
| Geoffrey S. Martha | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 55.32 per share. | 28 Jun 2021 | 11,500 | 93,448 (0%) | 0% | 55.3 | 636,180 | Ordinary Shares |
| Geoffrey S. Martha | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2021 | 11,500 | 1,481 | - | - | Stock Option (Right to Buy) | |
| Geoffrey S. Martha | Director, CEO | Sale of securities on an exchange or to another person at price $ 125.29 per share. | 28 Jun 2021 | 11,500 | 81,948 (0%) | 0% | 125.3 | 1,440,835 | Ordinary Shares |
| Karen L. Parkhill | EVP & Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 22 Jun 2021 | 238 | 843 (0%) | 0% | 0 | Ordinary Shares | |
| Karen L. Parkhill | EVP & Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 22 Jun 2021 | 238 | 85,747 (0%) | 0% | 0 | Ordinary Shares | |
| Karen L. Parkhill | EVP & Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 22 Jun 2021 | 238 | 843 (0%) | 0% | 0 | Ordinary Shares | |
| Karen L. Parkhill | EVP & Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 22 Jun 2021 | 238 | 843 (0%) | 0% | 0 | Ordinary Shares | |
| Karen L. Parkhill | EVP & Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 22 Jun 2021 | 238 | 85,985 (0%) | 0% | 0 | Ordinary Shares | |
| Karen L. Parkhill | EVP & Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 22 Jun 2021 | 238 | 85,509 (0%) | 0% | 0 | Ordinary Shares | |
| Brett A. Wall | EVP & Pres Neuroscience | Payment of exercise price or tax liability using portion of securities received from the company at price $ 123.23 per share. | 18 Jun 2021 | 938 | 21,717 (0%) | 0% | 123.2 | 115,590 | Ordinary Shares |
| Brett A. Wall | EVP & Pres Neuroscience | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2021 | 1,168 | 6,850 | - | - | Stock Option (Right to Buy) | |
| Brett A. Wall | EVP & Pres Neuroscience | Sale of securities on an exchange or to another person at price $ 123.50 per share. | 18 Jun 2021 | 115 | 21,602 (0%) | 0% | 123.5 | 14,203 | Ordinary Shares |
| Brett A. Wall | EVP & Pres Neuroscience | Exercise or conversion of derivative security received from the company (such as an option) at price $ 74.84 per share. | 18 Jun 2021 | 1,168 | 22,655 (0%) | 0% | 74.8 | 87,413 | Ordinary Shares |
| Karen L. Parkhill | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 124.47 per share. | 15 Jun 2021 | 605 | 86,223 (0%) | 0% | 124.5 | 75,304 | Ordinary Shares |
| Brett A. Wall | EVP & Pres Neuroscience | Sale of securities on an exchange or to another person at price $ 128.07 per share. | 28 May 2021 | 2,473 | 21,487 (0%) | 0% | 128.1 | 316,717 | Ordinary Shares |
| Brett A. Wall | EVP & Pres Neuroscience | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.00 per share. | 28 May 2021 | 12,300 | 31,315 (0%) | 0% | 47 | 578,100 | Ordinary Shares |
| Brett A. Wall | EVP & Pres Neuroscience | Payment of exercise price or tax liability using portion of securities received from the company at price $ 126.59 per share. | 28 May 2021 | 7,355 | 23,960 (0%) | 0% | 126.6 | 931,069 | Ordinary Shares |
| Brett A. Wall | EVP & Pres Neuroscience | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2021 | 12,300 | 0 | - | - | Stock Option (Right to Buy) | |
| John R. Liddicoat | EVP & President of Americas | Exercise or conversion of derivative security received from the company (such as an option) at price $ 78.00 per share. | 28 May 2021 | 1,283 | 60,929 (0%) | 0% | 78 | 100,074 | Ordinary Shares |
| John R. Liddicoat | EVP & President of Americas | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2021 | 17,095 | 0 | - | - | Stock Option (Right to Buy) | |
| John R. Liddicoat | EVP & President of Americas | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2021 | 1,283 | 0 | - | - | Stock Option (Right to Buy) | |
| John R. Liddicoat | EVP & President of Americas | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2021 | 1,136 | 0 | - | - | Stock Option (Right to Buy) | |
| John R. Liddicoat | EVP & President of Americas | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2021 | 15,142 | 0 | - | - | Stock Option (Right to Buy) | |
| John R. Liddicoat | EVP & President of Americas | Exercise or conversion of derivative security received from the company (such as an option) at price $ 78.00 per share. | 28 May 2021 | 17,095 | 59,646 (0%) | 0% | 78 | 1,333,410 | Ordinary Shares |
| John R. Liddicoat | EVP & President of Americas | Exercise or conversion of derivative security received from the company (such as an option) at price $ 88.06 per share. | 28 May 2021 | 15,142 | 77,207 (0%) | 0% | 88.1 | 1,333,405 | Ordinary Shares |
| John R. Liddicoat | EVP & President of Americas | Exercise or conversion of derivative security received from the company (such as an option) at price $ 88.06 per share. | 28 May 2021 | 1,136 | 62,065 (0%) | 0% | 88.1 | 100,036 | Ordinary Shares |
| John R. Liddicoat | EVP & President of Americas | Sale of securities on an exchange or to another person at price $ 126.65 per share. | 28 May 2021 | 34,656 | 42,551 (0%) | 0% | 126.6 | 4,389,182 | Ordinary Shares |
| Craig Arnold | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2021 | 1,334 | 32,954 (0%) | 0% | 0 | Ordinary Shares | |
| Denise M. O'Leary | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2021 | 1,334 | 68,745 (0%) | 0% | 0 | Ordinary Shares | |
| Kendall J. Powell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2021 | 1,334 | 35,466 (0%) | 0% | 0 | Ordinary Shares | |
| Randall J. Hogan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2021 | 1,334 | 2,682 (0%) | 0% | 0 | Ordinary Shares | |
| Richard H. Anderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2021 | 1,334 | 103,050 (0%) | 0% | 0 | Ordinary Shares | |
| James T. Lenehan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2021 | 1,334 | 57,849 (0%) | 0% | 0 | Ordinary Shares | |
| Scott C. Donnelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2021 | 1,334 | 13,349 (0%) | 0% | 0 | Ordinary Shares | |
| Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2021 | 820 | 820 (0%) | 0% | 0 | Ordinary Shares | |
| Michael O. Leavitt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2021 | 1,334 | 21,779 (0%) | 0% | 0 | Ordinary Shares | |
| Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2021 | 1,334 | 10,353 (0%) | 0% | 0 | Ordinary Shares | |
| Andrea J. Goldsmith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2021 | 1,334 | 2,985 (0%) | 0% | 0 | Ordinary Shares | |
| Craig Arnold | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 129.97 per share. | 27 Apr 2021 | 426 | 31,620 (0%) | 0% | 130.0 | 55,367 | Ordinary Shares |
| Denise M. O'Leary | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 129.97 per share. | 27 Apr 2021 | 426 | 67,411 (0%) | 0% | 130.0 | 55,367 | Ordinary Shares |
| Kendall J. Powell | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 129.97 per share. | 27 Apr 2021 | 426 | 34,132 (0%) | 0% | 130.0 | 55,367 | Ordinary Shares |
| Randall J. Hogan | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 129.97 per share. | 27 Apr 2021 | 426 | 1,348 (0%) | 0% | 130.0 | 55,367 | Ordinary Shares |
| Richard H. Anderson | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 129.97 per share. | 27 Apr 2021 | 426 | 101,716 (0%) | 0% | 130.0 | 55,367 | Ordinary Shares |
| James T. Lenehan | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 129.97 per share. | 27 Apr 2021 | 426 | 56,515 (0%) | 0% | 130.0 | 55,367 | Ordinary Shares |
| Scott C. Donnelly | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 129.97 per share. | 27 Apr 2021 | 426 | 12,015 (0%) | 0% | 130.0 | 55,367 | Ordinary Shares |
| Elizabeth G. Nabel | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 129.97 per share. | 27 Apr 2021 | 426 | 9,019 (0%) | 0% | 130.0 | 55,367 | Ordinary Shares |
| Andrea J. Goldsmith | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 129.97 per share. | 27 Apr 2021 | 426 | 1,651 (0%) | 0% | 130.0 | 55,367 | Ordinary Shares |
| Geoffrey S. Martha | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2021 | 2,404 | 0 | - | - | Stock Option (Right to Buy) | |
| Geoffrey S. Martha | Director, CEO | Sale of securities on an exchange or to another person at price $ 118.83 per share. | 05 Apr 2021 | 9,308 | 81,938 (0%) | 0% | 118.8 | 1,106,070 | Ordinary Shares |
| Geoffrey S. Martha | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 55.32 per share. | 05 Apr 2021 | 9,308 | 91,246 (0%) | 0% | 55.3 | 514,919 | Ordinary Shares |
| Geoffrey S. Martha | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 41.60 per share. | 05 Apr 2021 | 2,404 | 84,342 (0%) | 0% | 41.6 | 100,006 | Ordinary Shares |
| Geoffrey S. Martha | Director, CEO | Sale of securities on an exchange or to another person at price $ 118.83 per share. | 05 Apr 2021 | 2,404 | 81,938 (0%) | 0% | 118.8 | 285,667 | Ordinary Shares |
| Geoffrey S. Martha | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2021 | 9,308 | 11,173 | - | - | Stock Option (Right to Buy) | |
| Karen L. Parkhill | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 119.12 per share. | 15 Mar 2021 | 632 | 86,556 (0%) | 0% | 119.1 | 75,284 | Ordinary Shares |
| Robert Ten Hoedt | EVP & President EMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2021 | 7,168 | 0 | - | - | Stock Option (Right to Buy) | |
| Robert Ten Hoedt | EVP & President EMEA | Sale of securities on an exchange or to another person at price $ 117.98 per share. | 02 Mar 2021 | 7,168 | 43,797 (0%) | 0% | 118.0 | 845,681 | Ordinary Shares |
| Robert Ten Hoedt | EVP & President EMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 34.88 per share. | 02 Mar 2021 | 7,168 | 50,965 (0%) | 0% | 34.9 | 250,020 | Ordinary Shares |
| Sean Salmon | EVP & Group President Diabetes | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 16,314 | 16,314 | - | - | Stock Option (Right to Buy) | |
| Sean Salmon | EVP & Group President Diabetes | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 1,979 | 30,007 (0%) | 0% | 0 | Ordinary Shares | |
| Sean Salmon | EVP & Group President Diabetes | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 4,947 | 4,947 | - | - | Performance Share Units | |
| Carol A. Surface | SVP, Chief HR Officer | Sale of securities on an exchange or to another person at price $ 114.90 per share. | 28 Dec 2020 | 15,000 | 34,150 (0%) | 0% | 114.9 | 1,723,500 | Ordinary Shares |
| Bradley E. Lerman | SVP General Counsel & Corp Sec | Sale of securities on an exchange or to another person at price $ 115.56 per share. | 22 Dec 2020 | 2,605 | 51,543 (0%) | 0% | 115.6 | 301,034 | Ordinary Shares |
| Robert J. White | EVP & Pres. Medical Surgical | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Dec 2020 | 1,500 | 55,852 (0%) | 0% | 0 | Ordinary Shares | |
| Robert J. White | EVP & Pres. Medical Surgical | Sale of securities on an exchange or to another person at price $ 115.46 per share. | 16 Dec 2020 | 10,930 | 44,922 (0%) | 0% | 115.5 | 1,261,978 | Ordinary Shares |
| Robert J. White | EVP & Pres. Medical Surgical | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Dec 2020 | 1,500 | 1,500 (0%) | 0% | 0 | Ordinary Shares | |
| Karen L. Parkhill | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 114.33 per share. | 15 Dec 2020 | 670 | 86,897 (0%) | 0% | 114.3 | 76,601 | Ordinary Shares |
| Bradley E. Lerman | SVP General Counsel & Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2020 | 19,918 | 0 | - | - | Stock Option (Right to Buy) | |
| Bradley E. Lerman | SVP General Counsel & Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 62.76 per share. | 09 Nov 2020 | 19,918 | 74,066 (0%) | 0% | 62.8 | 1,250,054 | Ordinary Shares |
| Bradley E. Lerman | SVP General Counsel & Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 62.76 per share. | 09 Nov 2020 | 797 | 74,863 (0%) | 0% | 62.8 | 50,020 | Ordinary Shares |
| Bradley E. Lerman | SVP General Counsel & Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2020 | 797 | 0 | - | - | Stock Option (Right to Buy) | |
| Bradley E. Lerman | SVP General Counsel & Corp Sec | Sale of securities on an exchange or to another person at price $ 113.13 per share. | 09 Nov 2020 | 20,715 | 54,148 (0%) | 0% | 113.1 | 2,343,488 | Ordinary Shares |
| Michael J. Coyle | EVP & Group Pres, Cardiac&Vasc | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.13 per share. | 03 Nov 2020 | 393 | 190,390 (0%) | 0% | 103.1 | 40,530 | Ordinary Shares |
| Richard E. Kuntz | SVP & Chief Medical & Science | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.13 per share. | 03 Nov 2020 | 273 | 74,009 (0%) | 0% | 103.1 | 28,154 | Ordinary Shares |
| Brett A. Wall | EVP & Group Pres Restora Thera | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.13 per share. | 03 Nov 2020 | 229 | 18,715 (0%) | 0% | 103.1 | 23,617 | Ordinary Shares |
| Bradley E. Lerman | SVP General Counsel & Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.13 per share. | 03 Nov 2020 | 337 | 54,148 (0%) | 0% | 103.1 | 34,755 | Ordinary Shares |
| Robert J. White | EVP & President MITG | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.13 per share. | 03 Nov 2020 | 299 | 57,352 (0%) | 0% | 103.1 | 30,836 | Ordinary Shares |
| John R. Liddicoat | EVP & President of Americas | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.13 per share. | 03 Nov 2020 | 128 | 41,989 (0%) | 0% | 103.1 | 13,201 | Ordinary Shares |
| Sean Salmon | EVP & Group President Diabetes | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.13 per share. | 03 Nov 2020 | 220 | 27,900 (0%) | 0% | 103.1 | 22,689 | Ordinary Shares |
| Omar Ishrak | Director, Executive Chairman | Gift of securities by or to the insider at price $ 0.00 per share. | 15 Oct 2020 | 8,650 | 8,650 (0%) | 0% | 0 | Ordinary Shares | |
| Omar Ishrak | Director, Executive Chairman | Gift of securities by or to the insider at price $ 0.00 per share. | 15 Oct 2020 | 8,650 | 9,532 (0%) | 0% | 0 | Ordinary Shares | |
| Randall J. Hogan | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 14 Oct 2020 | 36,798 | 36,798 (0%) | 0% | 0 | Ordinary Shares | |
| Randall J. Hogan | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 14 Oct 2020 | 36,798 | 1,747 (0%) | 0% | 0 | Ordinary Shares | |
| Michael J. Coyle | EVP & Group Pres, Cardiac&Vasc | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Oct 2020 | 21,164 | 21,164 | - | - | Performance Share Units | |
| Richard E. Kuntz | SVP & Chief Medical & Science | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Oct 2020 | 14,723 | 14,723 | - | - | Performance Share Units | |
| Brett A. Wall | EVP & Group Pres Restora Thera | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Oct 2020 | 14,723 | 14,723 | - | - | Performance Share Units | |
| Carol A. Surface | SVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Oct 2020 | 10,582 | 10,582 | - | - | Performance Share Units | |
| Omar Ishrak | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 108.40 per share. | 09 Oct 2020 | 763 | 561,032 (0%) | 0% | 108.4 | 82,709 | Ordinary Shares |
| Omar Ishrak | Director, Executive Chairman | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Oct 2020 | 5,900 | 566,932 (0%) | 0% | 0 | Ordinary Shares | |
| Omar Ishrak | Director, Executive Chairman | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Oct 2020 | 5,900 | 0 (0%) | 0% | 0 | Ordinary Shares | |
| Karen L. Parkhill | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Oct 2020 | 20,243 | 20,243 | - | - | Performance Share Units | |
| Bradley E. Lerman | SVP General Counsel & Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Oct 2020 | 18,173 | 18,173 | - | - | Performance Share Units | |
| Geoffrey S. Martha | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Oct 2020 | 51,758 | 51,758 | - | - | Performance Share Units | |
| Robert Ten Hoedt | EVP & President EMEA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Oct 2020 | 12,882 | 12,882 | - | - | Performance Share Units | |
| Robert J. White | EVP & President MITG | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Oct 2020 | 16,563 | 16,563 | - | - | Performance Share Units | |
| John R. Liddicoat | EVP & President of Americas | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Oct 2020 | 8,742 | 8,742 | - | - | Performance Share Units | |
| Sean Salmon | EVP & Group President Diabetes | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Oct 2020 | 11,042 | 11,042 | - | - | Performance Share Units | |
| Richard H. Anderson | Director | Purchase of securities on an exchange or from another person at price $ 108.52 per share. | 08 Oct 2020 | 4,607 | 101,673 (0%) | 0% | 108.5 | 499,952 | Ordinary Shares |
| Bradley E. Lerman | SVP General Counsel & Corp Sec | Sale of securities on an exchange or to another person at price $ 110.00 per share. | 08 Oct 2020 | 19,917 | 54,325 (0%) | 0% | 110 | 2,190,870 | Ordinary Shares |
| Bradley E. Lerman | SVP General Counsel & Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2020 | 797 | 797 | - | - | Stock Option (Right to Buy) | |
| Bradley E. Lerman | SVP General Counsel & Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2020 | 19,917 | 19,918 | - | - | Stock Option (Right to Buy) | |
| Bradley E. Lerman | SVP General Counsel & Corp Sec | Sale of securities on an exchange or to another person at price $ 110.00 per share. | 08 Oct 2020 | 797 | 54,325 (0%) | 0% | 110 | 87,670 | Ordinary Shares |